Paid Clinical Trials in Mobile, AL

As of September 2026, 127 paid clinical trials are recruiting in Mobile, Alabama. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 24, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

125 clinical trials

Get a weekly email when new trials open in Mobile, AL.

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

for Generalized Myasthenia Gravis

Drug: IMVT-1402

Sites in Mobile, Huntsville +46 more locations

Sponsor: Immunovant Sciences GmbH

Sex: All·Age: 18 - 80

Code: NCT07039916·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

for Acute Coronary Syndrome

Sites in Mobile, Fairhope +146 more locations

Sponsor: DalCor Pharmaceuticals

Sex: All·Age: 45+

Code: NCT05918861·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

for Chickenpox

Sites in Mobile +49 more locations

Sponsor: GlaxoSmithKline

Sex: All·Age: 12 Months - 15 Months·Accepts healthy volunteers

Code: NCT06740630·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

Sites in Mobile +35 more locations

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06525220·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

for Multiple Myeloma

Drug: Belantamab mafodotin

Sites in Mobile +29 more locations

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT06679101·Phase 3·Recruiting·Listed Nov 2024

Apply to this trial